Anai T, Hirota Y, Yoshimatsu J, Oga M, Miyakawa I
Department of Obstetrics and Gynecology, Oita Medical University, Japan.
Obstet Gynecol. 1993 Feb;81(2):251-4.
To assess the effect of prenatal vitamin K1 on the coagulation status of newborns.
We measured noncarboxylated prothrombin and performed the Normotest in two groups of 5-day-old infants whose mothers were given oral vitamin K1, 10 mg/day for 2 weeks at least 10 days before delivery, or were untreated.
Noncarboxylated prothrombin was found in one of 74 treated women and 13 of 186 controls, a nonsignificant difference. The mean (+/- standard deviation) Normotest value was 59.6 +/- 10.1% (range 38.9-84.4) for the treated group and 53.4 +/- 9.9% (range 16.3-89.9) for the controls, a statistically significant difference (P < .001).
Based on the Normotest results, we suggest that vitamin K crosses the placenta and persists to activate the vitamin K-dependent coagulant factors until at least the fifth day of life. Thus, prenatal vitamin K1 administration may replace prophylaxis at birth.
评估产前维生素K1对新生儿凝血状态的影响。
我们对两组5日龄婴儿进行了非羧化凝血酶原检测并进行了凝血正常检测,其中一组母亲在分娩前至少10天接受了口服维生素K1,10毫克/天,持续2周,另一组母亲未接受治疗。
74名接受治疗的女性中有1名检测出非羧化凝血酶原,186名对照组中有13名检测出,差异无统计学意义。治疗组凝血正常检测值的平均值(±标准差)为59.6±10.1%(范围38.9 - 84.4),对照组为53.4±9.9%(范围16.3 - 89.9),差异有统计学意义(P < .001)。
根据凝血正常检测结果,我们认为维生素K可穿过胎盘并持续激活维生素K依赖的凝血因子直至生命的至少第五天。因此,产前给予维生素K1可能可替代出生时的预防措施。